FASLG and cancer: MOTI-1001 consists of the anticancer drug, paclitaxel, loaded in particles (OncojansTM) which are coated with Fas extracellular domain. It binds to FasL which often overexpressed on some cancerous cells. The binding can inhibit the invasion or proliferation, induced by FasL and trigger an active intracellular uptake process akin to phagocytosis. The ingested drug carrier forms a local drug reservoir inside the cancer cells and slowly releases paclitaxel, which binds to tubulin and interferes with the cell’s cytoskeleton (88, 89)